Search research articles
Contact Us
Filters
Showing results (151-160 of 377) with videos related to
Page
of 38
Sort By:
Anticancer Research
|
February 4, 2019
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial
Amir Sonnenblick, Andrew Bailey, Beatrice Uziely, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2017
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Sherko Kümmel, Stefan Paepke, Jens Huober, et al.
Cancer Research
|
September 15, 2020
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
Min Huang, Joyce O'Shaughnessy, Jing Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 5, 2023
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041)
Peter A Fasching, Alexander Hein, Hans-Christian Kolberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
Volker Moebus, Christian Jackisch, Hans-Joachim Lueck, et al.
Breast Cancer Research and Treatment
|
June 18, 2013
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 11, 2021
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials
Jenny Furlanetto, Frederik Marmé, Sabine Seiler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations
Manfred Kaufmann, Gunter von Minckwitz, Roy Smith, et al.
Breast Cancer Research and Treatment
|
June 14, 2011
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)
Gunter von Minckwitz, Silvia Darb-Esfahani, Sibylle Loibl, et al.
Page
of 38
Search research articles
Search
Showing results (151-160 of 377) with videos related to
Sort By:
Page
of 38
Anticancer Research
|
February 4, 2019
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial
Amir Sonnenblick, Andrew Bailey, Beatrice Uziely, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2017
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Sherko Kümmel, Stefan Paepke, Jens Huober, et al.
Cancer Research
|
September 15, 2020
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
Min Huang, Joyce O'Shaughnessy, Jing Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 5, 2023
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041)
Peter A Fasching, Alexander Hein, Hans-Christian Kolberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
Volker Moebus, Christian Jackisch, Hans-Joachim Lueck, et al.
Breast Cancer Research and Treatment
|
June 18, 2013
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 11, 2021
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials
Jenny Furlanetto, Frederik Marmé, Sabine Seiler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations
Manfred Kaufmann, Gunter von Minckwitz, Roy Smith, et al.
Breast Cancer Research and Treatment
|
June 14, 2011
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)
Gunter von Minckwitz, Silvia Darb-Esfahani, Sibylle Loibl, et al.
Page
of 38